[Form 4] Mannkind Corporation Insider Trading Activity

Rhea-AI Filing Summary

Dominic Marasco, President of the Endocrine Business Unit at Mannkind, received a significant performance-based equity award on June 23, 2025. The insider was granted 1,000,000 performance restricted stock units (PRSUs) that represent the right to receive an equivalent number of common stock shares.

Key terms of the PRSU grant:

• Vesting date set for March 15, 2028
• Final payout ranges from 0% to 200% of target shares based on net sales performance
• Target amount is 1,000,000 shares, meaning maximum potential payout is 2,000,000 shares
• Exercise price of $0, making this a full-value award

This significant equity grant aligns the executive's interests with long-term company performance, specifically tied to net sales targets over an approximately 3-year performance period.

Positive

• President of Endocrine Business Unit granted 1,000,000 performance-based RSUs with potential 200% upside, aligning executive compensation with sales growth targets through 2028

Negative

• None.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Marasco Dominic

(Last) (First) (Middle)

1 CASPER STREET

(Street)

DANBURY CT 06810

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MANNKIND CORP [ MNKD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Pres, Endocrine Business Unit

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance Restricted Stock Unit	(1)	06/23/2025		A		1,000,000		(2)	(2)	Common Stock, $0.01 Par Value	1,000,000	$0	1,000,000	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of MNKD common stock.

2. The performance-based restricted stock unit will vest on March 15, 2028. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 5 above, will be determined by the achievement of a specified net sales target, with the potential payout ranging from 0% to 200%.

	/s/ Dominic Marasco	06/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many performance restricted stock units (PRSUs) did MNKD's President of Endocrine Business Unit receive in June 2025?

Dominic Marasco, MNKD's President of Endocrine Business Unit, received 1,000,000 performance restricted stock units on June 23, 2025.

When will MNKD's Dominic Marasco's PRSUs vest?

The performance-based restricted stock units will vest on March 15, 2028, subject to achieving specified net sales targets.

What is the potential payout range for MNKD's PRSUs granted to Dominic Marasco?

The potential payout ranges from 0% to 200% of the target (1,000,000 shares), depending on the achievement of specified net sales targets.

What position does Dominic Marasco hold at MNKD according to the Form 4?

According to the Form 4 filing, Dominic Marasco serves as the President of Endocrine Business Unit at MannKind Corporation.

What is the exercise price of MNKD's PRSUs granted to Marasco in June 2025?

The PRSUs were granted at $0 exercise price, with each unit representing a contingent right to receive one share of MNKD common stock upon vesting.